Investing.com -- TransCode Therapeutics (NASDAQ:RNAZ) stock surged 18% on Tuesday after the company published preclinical data showing its lead candidate TTX-MC138 demonstrated therapeutic potential ...
BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced today that its lead therapeutic candidate, TTX-MC138, demonstrated efficacy in preclinical models of glioblastoma multiforme (GBM), the ...
BOSTON, Jan. 6, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced ...
TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous injection TTX-MC138 demonstrated suppression of miR-10b target and extended survival in aggressive ...
Glioblastoma is the most aggressive primary brain cancer, with median survival under two years from diagnosis despite current standard-of-care interventions. The molecular target of TTX-MC138, ...
Abstract: Transcoding in video live-streaming systems requires a lot of computation and, hence, a lot of power. Putting a limit on the power drawn by each of the transcoding processors in a server ...
Abstract: This article reviews existing surveys and literature on holographic video communication, remote telepresence, and interaction. We first analyze the characteristics, key challenges, scenarios ...
TransCode Therapeutics ( (RNAZ)) just unveiled an announcement. On December 19, 2025, TransCode Therapeutics appointed veteran life sciences executive Jack E. Stover to its board of directors, ...
BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company focused on immuno-oncology and RNA treatments for advanced cancer, announced Monday the appointment of Jack E. Stover to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback